LY 2969822Alternative Names: LY-2969822
Latest Information Update: 19 May 2016
At a glance
- Originator Eli Lilly
- Mechanism of Action Metabotropic glutamate receptor 2 agonists; Metabotropic glutamate receptor 3 agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 12 Dec 2013 Eli Lilly plans a phase I trial in Healthy volunteers in Singapore (NCT02018887)
- 12 Dec 2013 Preclinical trials in Undefined indication in USA (PO)